Drug Interaction Report

Lansoprazole has a major potential interaction with Diarrhea.

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Pralsetinib has a moderate potential interaction with High Blood Pressure.

Hypertension has been reported in patients in treatment with pralsetinib. This drug should not be initiated in patients with uncontrolled hypertension. Caution and close monitoring is advised.

Pralsetinib has a moderate potential interaction with Hypocalcemia.

QT prolongation was reported in clinical trials in patients that received pralsetinib. Use with caution in patients with history of arrhythmias, QT prolongation or taking medications that can prolong the QT interval (e.g., strong CYP450 3A4 inhibitors). Monitor QT interval and serum electrolytes before initiation and regularly during treatment. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior and during treatment.

Pralsetinib has a moderate potential interaction with Hypokalemia.

QT prolongation was reported in clinical trials in patients that received pralsetinib. Use with caution in patients with history of arrhythmias, QT prolongation or taking medications that can prolong the QT interval (e.g., strong CYP450 3A4 inhibitors). Monitor QT interval and serum electrolytes before initiation and regularly during treatment. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior and during treatment.

Lansoprazole has a moderate potential interaction with Liver Disease.

Lansoprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.

Pralsetinib has a moderate potential interaction with Liver Disease.

Pralsetinib has not been studied in patients with moderate or severe hepatic impairment. Additionally, clinical trials reported hepatotoxicity in some patients receiving treatment. Caution and close monitoring is advised if administering in patients with hepatic impairment.

Pralsetinib has a moderate potential interaction with Long QT Syndrome.

QT prolongation was reported in clinical trials in patients that received pralsetinib. Use with caution in patients with history of arrhythmias, QT prolongation or taking medications that can prolong the QT interval (e.g., strong CYP450 3A4 inhibitors). Monitor QT interval and serum electrolytes before initiation and regularly during treatment. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior and during treatment.

Lansoprazole has a moderate potential interaction with Magnesium Imbalance.

Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.

Pralsetinib has a moderate potential interaction with Magnesium Imbalance.

QT prolongation was reported in clinical trials in patients that received pralsetinib. Use with caution in patients with history of arrhythmias, QT prolongation or taking medications that can prolong the QT interval (e.g., strong CYP450 3A4 inhibitors). Monitor QT interval and serum electrolytes before initiation and regularly during treatment. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior and during treatment.

Lansoprazole has a moderate potential interaction with Osteoporosis.

Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.

Lansoprazole has a major potential interaction with Pseudomembranous Colitis.

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Pralsetinib has a moderate potential interaction with Renal Dysfunction.

Pralsetinib has not been studied in patients with severe renal impairment or end-stage renal disease. Caution is advised if administering in these patients.